Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (21473)	5/28/1998 1:06:00 PM
From: medsunman	Read Replies (2) \| Respond to of 32384

Dear Henry: On Monday Peter Singleton posted some comments re info presented by Robinson at the annual meeting. One of his comments was that Targretin approval for diabetes seemed unlikely. Apparently Peter based this conclusion on Robinson's remarks to the effect that toxicity was unacceptable in this patient population, and that they were now trying smaller doses. Peter said he would be pleasantly surprised if Targretin moves to PIII testing. I find this to be very disquieting, and would like to hear from you on this subject. Thanks, Medsunman